NfL reliability across laboratories, stage-dependent diagnostic performance and matrix comparability in genetic FTD: a large GENFI study

Christoph Linnemann,Carlo Wilke,David Mengel,Henrik Zetterberg,Carolin Heller,Jens Kuhle,Arabella Bouzigues,Lucy L Russell,Phoebe H Foster,Eve Ferry-Bolder,John Cornelis Van Swieten,Lize C Jiskoot,Harro Seelaar,Fermin Moreno,Barbara Borroni,Raquel Sánchez-Valle,Daniela Galimberti,Robert Laforce,Caroline Graff,Mario Masellis,Maria Carmela Tartaglia,James Benedict Rowe,Elizabeth Finger,Rik Vandenberghe,Alexandre de Mendonca,Chris R Butler,Alexander Gerhard,Simon Ducharme,Isabelle L E Ber,Pietro Tiraboschi,Isabel Santana,Florence Pasquier,Johannes Levin,Markus Otto,Sandro Sorbi,Jonathan Daniel Rohrer,Matthis Synofzik
DOI: https://doi.org/10.1136/jnnp-2023-332464
2024-01-19
Abstract:Background Blood neurofilament light chain (NfL) is increasingly considered as a key trial biomarker in genetic frontotemporal dementia (gFTD). We aimed to facilitate the use of NfL in gFTD multicentre trials by testing its (1) reliability across labs; (2) reliability to stratify gFTD disease stages; (3) comparability between blood matrices and (4) stability across recruiting sites. Methods Comparative analysis of blood NfL levels in a large gFTD cohort (GENFI) for (1)–(4), with n=344 samples (n=148 presymptomatic, n=11 converter, n=46 symptomatic subjects, with mutations in C9orf72 , GRN or MAPT ; and n=139 within-family controls), each measured in three different international labs by Simoa HD-1 analyzer. Results NfL revealed an excellent consistency (intraclass correlation coefficient (ICC) 0.964) and high reliability across the three labs (maximal bias (pg/mL) in Bland-Altman analysis: 1.12±1.20). High concordance of NfL across laboratories was moreover reflected by high areas under the curve for discriminating conversion stage against the (non-converting) presymptomatic stage across all three labs. Serum and plasma NfL were largely comparable (ICC 0.967). The robustness of NfL across 13 recruiting sites was demonstrated by a linear mixed effect model. Conclusions Our results underline the suitability of blood NfL in gFTD multicentre trials, including cross-lab reliable stratification of the highly trial-relevant conversion stage, matrix comparability and cross-site robustness.
surgery,psychiatry,clinical neurology
What problem does this paper attempt to address?